Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer.
Fong L, Hotson A, Powderly JD, Sznol M, Heist RS, Choueiri TK, George S, Hughes BGM, Hellmann MD, Shepard DR, Rini BI, Kummar S, Weise AM, Riese MJ, Markman B, Emens LA, Mahadevan D, Luke JJ, Laport G, Brody JD, Hernandez-Aya L, Bonomi P, Goldman JW, Berim L, Renouf DJ, Goodwin RA, Munneke B, Ho PY, Hsieh J, McCaffery I, Kwei L, Willingham SB, Miller RA. Fong L, et al. Among authors: willingham sb. Cancer Discov. 2020 Jan;10(1):40-53. doi: 10.1158/2159-8290.CD-19-0980. Epub 2019 Nov 15. Cancer Discov. 2020. PMID: 31732494 Free PMC article. Clinical Trial.
Targeting the A2AR in cancer; early lessons from the clinic.
Willingham SB, Hotson AN, Miller RA. Willingham SB, et al. Curr Opin Pharmacol. 2020 Aug;53:126-133. doi: 10.1016/j.coph.2020.08.003. Epub 2020 Sep 29. Curr Opin Pharmacol. 2020. PMID: 33002857 Free article. Review.
Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response.
Tseng D, Volkmer JP, Willingham SB, Contreras-Trujillo H, Fathman JW, Fernhoff NB, Seita J, Inlay MA, Weiskopf K, Miyanishi M, Weissman IL. Tseng D, et al. Among authors: willingham sb. Proc Natl Acad Sci U S A. 2013 Jul 2;110(27):11103-8. doi: 10.1073/pnas.1305569110. Epub 2013 May 20. Proc Natl Acad Sci U S A. 2013. PMID: 23690610 Free PMC article.
The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors.
Willingham SB, Volkmer JP, Gentles AJ, Sahoo D, Dalerba P, Mitra SS, Wang J, Contreras-Trujillo H, Martin R, Cohen JD, Lovelace P, Scheeren FA, Chao MP, Weiskopf K, Tang C, Volkmer AK, Naik TJ, Storm TA, Mosley AR, Edris B, Schmid SM, Sun CK, Chua MS, Murillo O, Rajendran P, Cha AC, Chin RK, Kim D, Adorno M, Raveh T, Tseng D, Jaiswal S, Enger PØ, Steinberg GK, Li G, So SK, Majeti R, Harsh GR, van de Rijn M, Teng NN, Sunwoo JB, Alizadeh AA, Clarke MF, Weissman IL. Willingham SB, et al. Proc Natl Acad Sci U S A. 2012 Apr 24;109(17):6662-7. doi: 10.1073/pnas.1121623109. Epub 2012 Mar 26. Proc Natl Acad Sci U S A. 2012. PMID: 22451913 Free PMC article.
Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma.
Edris B, Weiskopf K, Volkmer AK, Volkmer JP, Willingham SB, Contreras-Trujillo H, Liu J, Majeti R, West RB, Fletcher JA, Beck AH, Weissman IL, van de Rijn M. Edris B, et al. Among authors: willingham sb. Proc Natl Acad Sci U S A. 2012 Apr 24;109(17):6656-61. doi: 10.1073/pnas.1121629109. Epub 2012 Mar 26. Proc Natl Acad Sci U S A. 2012. PMID: 22451919 Free PMC article.
Anti-KIT monoclonal antibody inhibits imatinib-resistant gastrointestinal stromal tumor growth.
Edris B, Willingham SB, Weiskopf K, Volkmer AK, Volkmer JP, Mühlenberg T, Montgomery KD, Contreras-Trujillo H, Czechowicz A, Fletcher JA, West RB, Weissman IL, van de Rijn M. Edris B, et al. Among authors: willingham sb. Proc Natl Acad Sci U S A. 2013 Feb 26;110(9):3501-6. doi: 10.1073/pnas.1222893110. Epub 2013 Feb 4. Proc Natl Acad Sci U S A. 2013. PMID: 23382202 Free PMC article.
30 results